Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

Tarsus Pharmaceuticals appointed Neera Clase as Chief Commercial Officer effective Nov. 1, 2026, converting her interim role that began in July 2026 into a permanent position. Clase previously served as SVP of Market Access at Tarsus and has 25+ years of biopharma experience at Acadia, Relypsa, and Abbott. She will lead commercial strategy for XDEMVY and planning across the pipeline, including two Phase 3 retina programs. She stated XDEMVY has potential to exceed $2 billion in peak sales, framing expanded patient reach as her first priority.

•4d ago

Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, adding worldwide rights to gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine targeting the underlying biology of Stargardt disease. ALK-001 is being evaluated in the global NORTHSTAR Phase 3 trial with topline data anticipated in 2029, and carries FDA Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations. Tarsus views ALK-001 as a potential blockbuster in one of the largest inherited retinal diseases; Stargardt affects an estimated 86,000 people in the United States and currently has no FDA-approved therapy. The deal, first announced August 6, 2026, closed after satisfaction of customary conditions, and joins Tarsus' FDA-approved XDEMVY plus Phase 2 pipeline assets TP-04, TP-05 and IRX-101.

•1mo ago

Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease

Alkeus Pharmaceuticals published TEASE-1 results in JAMA Ophthalmology showing oral gildeuretinol met its primary endpoint in Stargardt disease, delivering a statistically significant 21.6% reduction in the transformed growth rate of retinal atrophic lesions versus untreated patients (p<0.001). Safety over 24 months was clean, with no reports of delayed dark adaptation or night blindness, and prespecified sensitivity analyses showed a 29.3% reduction in untransformed lesion growth rate across consistent subgroups. For Tarsus Pharmaceuticals (TARS), the data strengthen the profile of gildeuretinol ahead of its pending acquisition of Alkeus, announced August 6, 2026 and expected to close in 2026, subject to customary closing conditions. The lead asset is now advancing in the global Phase 3 NORTHSTAR trial targeting roughly 230 participants, while the release cautions there is no assurance the acquisition will be consummated on the stated terms or timing.

•1mo ago

Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease

Alkeus Pharmaceuticals, the pending acquisition target of Tarsus Pharmaceuticals, secured Orphan Drug Designation from Japan's MHLW for oral gildeuretinol to treat Stargardt disease. The designation grants eligibility for development cost subsidies and potential market exclusivity for up to 10 years, enhancing the commercial profile of the drug currently in a global Phase 3 trial. Tarsus announced a definitive agreement to acquire Alkeus on August 6, 2026, with the transaction expected to close in 2026 subject to regulatory approvals and customary conditions.

•2mo ago

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

Tarsus reported Q2 revenue of $173.9 million, up 69% year-over-year, driven by record XDEMVY sales and improved gross-to-net performance. The company raised full-year 2026 XDEMVY sales guidance to $685-705 million and announced a pending acquisition of Alkeus Pharmaceuticals to secure a Phase 3 asset for Stargardt disease. To fund the acquisition, Tarsus priced a $125 million private placement financing and ended the quarter with $449.7 million in cash and marketable securities.

•2mo ago

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million in upfront consideration, consisting of $270 million in cash and $180 million in stock. The acquisition centers on ALK-001 (gildeuretinol), a Phase 3 oral therapy for Stargardt disease with Breakthrough Therapy and Orphan Drug designations. Top-line data from the Phase 3 NORTHSTAR trial is expected in the second half of 2029, and the transaction is anticipated to close in 2026 subject to regulatory approvals.

•2mo ago

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

Tarsus Pharmaceuticals acquired iRenix Medical, securing IRX-101, a late-stage ocular antiseptic that demonstrated statistically significant reductions in post-procedural pain and corneal staining in a Phase 2b/3 trial. The transaction includes approximately $75 million in upfront consideration, split evenly between cash and stock, with potential milestone payments of up to $490 million tied to approval and commercial success. Tarsus plans to initiate an FDA-aligned Phase 3 study in the first half of 2027, targeting the large market of patients requiring intravitreal injections.

•3mo ago

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

Achieve Life Sciences appointed Jeffrey Farrow and Reid Waldman, MD to its Board of Directors to bolster commercial and strategic oversight ahead of its NDA resubmission for cytisinicline. Farrow brings extensive late-stage launch experience, having served as CFO for three biopharma companies acquired for a combined $9 billion, including Global Blood Therapeutics and Hyperion Therapeutics. Waldman, CEO of Veradermics (MANE), adds clinical and commercial expertise in dermatology and aesthetics, having led his company through a $294.8M IPO and subsequent $472M follow-on financing. The appointments signal management’s focus on building a board with deep operational experience in navigating FDA approvals and commercial launches for specialty pharmaceuticals.

•4mo ago